Date Closed

January 27, 2009

Lead Office

Toronto

On January 27, 2009, Chr. Hansen acquired all of the issued and outstanding shares of Urex Biotech Inc. The terms of the transaction were not disclosed.

Urex Biotech is headquartered in London, Ontairo. Urex is a convenient oral probiotic concept clinically documented to restore and maintain a healthy vaginal flora which may reduce the risk of infections. Over the last few years nine clinical studies conducted in several countries have been published using the oral formulation and numerous others are currently underway.

Chr. Hansen, headquartered in Horsholm, Denmark, is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments.

McCarthy Tétrault LLP represented Chr. Hansen, as acquirer, with a team led by Garth Girvan and Lara Nathans.